LES ECHOS 30/04/20 Coronavirus : les laboratoires de recherche P4, en 7 questions. WIKIPEDIA - Wuhan Institute of Virology. Facility in Wuhan, China The Wuhan Institute of Virology, Chinese Academy of Sciences (WIV; Chinese: 中国科学院武汉病毒研究所; pinyin: Zhōngguó Kēxuéyuàn Wǔhàn Bìngdú Yánjiūsuǒ) is a research institute on virology administered by the Chinese Academy of Sciences (CAS).
Located in Jiangxia District, Wuhan, Hubei, it opened mainland China's first biosafety level 4 (BSL–4) laboratory in 2015. In January 2020, conspiracy theories circulated that the 2019-20 coronavirus pandemic originated from viruses engineered by the WIV, which were refuted on the basis of scientific evidence that the virus has natural origins. History The WIV was founded in 1956 as the Wuhan Microbiology Laboratory under the Chinese Academy of Sciences (CAS). The WIV was a topic of controversy during the early months of the 2020 coronavirus pandemic. 2019–20 coronavirus pandemic. WIKIPEDIA - Institut de virologie de Wuhan. L'Institut de virologie de Wuhan (chinois : 中国科学院武汉病毒研究所 ; pinyin : Zhōngguó Kēxuéyuàn Wǔhàn Bìngdú Yánjiūsuǒ) est un institut de recherche en virologie administré par l'Académie chinoise des sciences et situé dans le district de Jiangxia à Wuhan, capitale de la province du Hubei.
En 2015, l'institut ouvre un laboratoire P4, le premier en Chine. Fondation et premiers développements[modifier | modifier le code] Le laboratoire de microbiologie de Wuhan est fondé en 1956 par le virologiste Gao Shangyin et le microbiologiste Chen Huagui, sous l'administration de l'Académie chinoise des sciences. Antiviral Research Volume 172, December 2019, The Biosafety Level 4 Zoonotic Laboratory Network (BSL4ZNet): Report of a workshop on live animal handling. The Biosafety Level 4 Zoonotic Laboratory Network (BSL4ZNet) was established in 2016, to provide a means of communication and support for the global high-containment laboratory community.
Journal of Biosafety and Biosecurity Volume 1, Issue 2, September 2019, Current status and future challenges of high-level biosafety laboratories in China. 1.
Introduction. INSERM - 2017 - SCIENCE & SOCIETE « Le laboratoire P4 de Wuhan, une réussite pour la coopération franco-chinoise » ROBIN DES BOIS 17/04/20 P4-Contre le virus du secret. Rappel.
Communiqué du 16 mars 2020 Robin des Bois souhaite que le gouvernement convoque au sujet du COVID-19 une instance d’information et de concertation (prévention, gestion de crise, gestion des déchets, retour à la normale …) à l’image du Haut comité pour la transparence et l’information sur la sécurité nucléaire -HCTISN. Journal of Biosafety and Biosecurity Volume 1, Issue 1, March 2019, Networking for training Level 3/4 biosafety laboratory staff. Emerging and re-emerging infections and possible bioterrorism acts will continue to challenge both the medical community and civilian populations worldwide.
Such events range from the use of anthrax in terrorist events to real international emergencies such as the severe acute respiratory syndrome (SARS) and 2014–15 Ebola epidemics, and the influenza pandemic that is expected to occur in future. These experiences have taught us a very important lesson; that a national/global health crisis can be effectively countered and brought to an end through a national/international effort involving effective communication and cooperation, as opposed to local initiatives or uncoordinated actions. Networking among Level 3/4 biosafety laboratories (BSL-3/4s) is one of the major approaches to enhancing preparedness for emergencies and tackling potential challenges. Good biosafety laboratory practices cannot be developed without a strong safety culture. Flexible modularized theoretical training.
Biosafety and Health Volume 1, Issue 2, September 2019, Laboratory biosafety in China: past, present, and future. I began my career in infectious disease control and prevention in the 1980s after I graduated from Peking Medical University.
In the early 1990s, as the director of the Technical Guidance Office of the Chinese Academy of Preventive Medicine, I participated in the accreditation of the first batch of biosafety level 3 (BSL-3) laboratories for HIV research in China. In the meantime, I held a concurrent position in the Infectious Disease Supervision and Management Office of the Ministry of Health of China. During the severe acute respiratory syndrome (SARS) epidemic, as a deputy leader of the Field Supervision Group, I was entrusted with the mission at the critical and tough moment to fight against this significant pathogen along with my colleagues. I would like to use the word “dedication” to describe the generation of experts who initiated the laboratory biosafety (LB) project in China. 1. 1.1. 1.2. 1.3. 1.4. CDC EID - MAI 2019 - Biosafety Level 4 Laboratory User Training Program, China.
Author affiliations: Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China Over the last 2 decades, numerous infectious diseases, including Ebola, Marburg hemorrhagic fever, Crimean-Congo hemorrhagic fever, Lassa fever, severe acute respiratory syndrome (SARS), avian influenza A(H5N1), Rift Valley fever, and Nipah and Hendra viral diseases, have emerged and re-emerged.
These infectious diseases pose serious threats to public health and global economies. For example, 28,616 suspected cases and 11,310 deaths were reported during the large and complex Ebola outbreak in West Africa during 2013–2016 (1). In addition, as the threat of terrorism increases globally, the risk for bioterrorism is expected to increase as well. To prepare for biological threats, scientists must research dangerous pathogens to develop effective methods to prevent, diagnose, and treat the diseases caused by them.
Training Program Overview Figure. CDC 19/03/19 Laboratory Biosafety and COVID-19: Questions and Answers. Aerosols and droplets containing particles that are <100 μm in diameter are not visible to the naked eye.
Laboratory workers may not be aware that such particles can be generated during many laboratory procedures and that these particles could be inhaled or could cross-contaminate work surfaces, materials, and equipment. Infectious aerosols are small liquid or solid particles suspended in the air that contain infectious agents. They can disperse throughout the laboratory and remain infective over time and distance. These particles are of a size that may be inhaled into the lower respiratory tract (<5 μm in diameter). OIE - 2020 - Testing of Human diagnostic specimens in Veterinary Laboratories. OMS 12/02/20 Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19)